Randox
A Northern Irish in vitro diagnostics and health technology company serving clinical, research, forensic, veterinary, food-testing and molecular laboratories.
Last updated August 25, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Randox is a privately held Northern Irish diagnostics and health technology company headquartered in Crumlin, County Antrim. Founded in 1982 by Peter FitzGerald, it develops, manufactures and markets laboratory reagents, diagnostic systems and testing services for hospitals, clinical laboratories, research institutions, molecular laboratories, food-testing operations, forensic toxicology, veterinary medicine and the wider life-sciences sector. Its activities span both instruments and consumables, allowing the company to participate in laboratory workflows rather than focusing on a single disease area or testing platform. The company has built an international distribution network serving approximately 145 countries. Its portfolio includes clinical chemistry and immunoassay products, quality-control materials, multiplex testing technologies, molecular diagnostic systems and specialist toxicology services. Randox also operates consumer-facing and clinical testing activities through Randox Health, while its laboratory-services operations have included forensic toxicology and large-scale infectious-disease testing. The breadth of these activities gives the brand a hybrid identity: it is simultaneously a business-to-business laboratory supplier, a testing-services provider and, in selected markets, a direct-to-consumer health brand. Randox expanded its research and manufacturing footprint during the 2010s. In 2014 it announced a €25 million investment in Dungloe, County Donegal, intended to support research, engineering and life-sciences employment. In 2019 it moved into the Randox Science Park, a 45-acre research and manufacturing site developed on the former Massereene Barracks site. The company also purchased Boston House in Fitzroy Square, London, in 2022, with plans to convert it into the Randox Institute, an education and personalised-healthcare centre. Randox became particularly prominent during the COVID-19 pandemic. The United Kingdom government awarded the company major contracts for coronavirus testing, including a reported £133 million contract in May 2020 and a further six-month extension valued at £347 million later that year. Across the pandemic period, government awards to Randox were reported at approximately £777 million, while the company supplied around 23 million tests. The contracts generated rapid revenue and profit growth but also attracted scrutiny over procurement, laboratory operations, testing-kit safety and the role of political advisers. The National Audit Office later stated that the government had not adequately documented key decisions and that the audit trail was insufficient for positive assurance, while also saying it had seen no evidence that the contracts were improperly awarded. The company has also faced serious reputational challenges. Its forensic toxicology business became the subject of a major investigation after allegations that laboratory data had been manipulated. The issue led to arrests, dropped prosecutions and reviews of thousands of criminal cases. Separately, Randox has faced criticism and legal actions concerning employment practices, public-sector lobbying, workplace language policies and advertising for a genetic risk test. These controversies sit alongside the company’s continuing expansion in diagnostics, molecular testing and personalised healthcare.
History
Randox was established in 1982 in Crumlin, County Antrim, by Peter FitzGerald, who remains identified as the company’s owner. From its Northern Irish base, the business developed into an in vitro diagnostics manufacturer and laboratory-services provider. Its early and continuing model has involved supplying reagents, instruments and related products to professional laboratories rather than operating solely as a consumer healthcare brand. Over time, Randox broadened its scope across clinical chemistry, immunoassay, molecular diagnostics, research, food analysis, veterinary testing and forensic toxicology. This diversification allowed the company to serve hospitals and clinical laboratories alongside specialist public-sector and commercial customers. The company’s international distribution network eventually extended to approximately 145 countries. By 2020, Randox was reported to employ about 2,700 people. The company increased its investment in research and manufacturing infrastructure during the 2010s. In 2014, it committed €25 million to a site in Dungloe, County Donegal. The investment was intended to support research, engineering and life-sciences activity and was associated with a target of more than 470 jobs by 2020. In 2019, Randox moved into the Randox Science Park, a 45-acre research and manufacturing complex developed on the former Massereene Barracks site. Randox Health also became a visible public-facing arm of the organization, including through its sponsorship of the Grand National at Aintree, which began in 2017. Randox’s forensic toxicology operations became embroiled in a major UK criminal-justice controversy. After Randox acquired a Manchester laboratory from Trimega Laboratories in 2014, allegations emerged that data at Randox Testing Services had been manipulated. Two employees were arrested in 2017 on suspicion of perverting the course of justice. The affair contributed to the abandonment of approximately 50 driving-related prosecutions by November 2017 and prompted reviews of more than 10,000 cases, including cases involving sexual and violent offences. In 2021, Greater Manchester Police said that as many as 27,000 cases could potentially be affected. Randox agreed to provide £2.5 million toward a National Police Chiefs’ Council retesting programme. The company’s corporate structure also attracted attention. In March 2020, Randox was restructured so that it was ultimately held by Randox (IOM) Ltd in the Isle of Man. The company said the arrangement was intended to support a future transfer of ownership to later generations; press coverage questioned whether the structure could also reduce tax liabilities. The same year, Randox became a major supplier in the UK’s COVID-19 testing programme. It received large contracts from the Department of Health and Social Care, including a reported £133 million initial award and a £347 million extension. Further pandemic-related awards brought the reported total to approximately £777 million, with around 23 million tests supplied. COVID-19 testing transformed Randox’s financial scale and public profile. Reported sales rose from £118 million in 2018 to £218 million for the period from January 2019 to June 2020 and then to £619 million in the following year. The company moved from making a loss before June 2020 to reporting a pre-tax profit of £275 million in the subsequent year. These figures were reported in connection with pandemic contracts and should be understood in their stated accounting periods. The arrangements also attracted scrutiny over non-competitive procurement and laboratory management. In March 2022, the National Audit Office criticized the government’s documentation of procurement decisions but said it had found no evidence that Randox contracts had been awarded improperly. Randox continued to expand its institutional and personalised-health ambitions. In 2022, it bought Boston House in London’s Fitzroy Square for a reported £29 million and was expected to invest a further £15 million to convert it into the Randox Institute, an education and personalised-healthcare centre. Its direct-to-consumer activities later drew criticism when advertising for a Type 1 diabetes genetic risk assessment assay was removed in 2024 after concerns that the messaging was fear-based. The company has also faced employment-related disputes. Reported cases included a successful claim concerning weight discrimination, an unfair-dismissal award to a former international business manager, and a maternity-pay dispute supported by Unite legal services. In 2021, notices at Randox’s Donegal facility reportedly prohibited employees from speaking languages other than English. The notices were withdrawn after criticism, including because the facility operated in an Irish-speaking area supported by Údarás na Gaeltachta. Randox remains an active, privately held diagnostics business with activities spanning laboratory products, testing services, molecular medicine and personalised healthcare.
- 2022
Boston House acquisition
[1]Randox purchases Boston House in London for development as the planned Randox Institute.
- 2020
Corporate restructuring
[1]Randox is restructured so that it is ultimately held by Randox (IOM) Ltd in the Isle of Man.
- 2020
Major UK COVID-19 testing contracts
[1]Randox receives large UK government contracts to provide coronavirus testing.
- 2019
Randox Science Park opens
[1]The company moves into a 45-acre research and manufacturing site on the former Massereene Barracks property.
- 2017
Grand National sponsorship begins
[1]Randox Health begins sponsoring the Grand National at Aintree racecourse.
- 2017
Forensic toxicology investigation becomes public
[1]Employees are arrested amid allegations of data manipulation at Randox Testing Services, affecting criminal cases.
- 2014
Dungloe research and manufacturing investment
[1]Randox announces a €25 million investment in a County Donegal site for research, engineering and life-sciences activity.
- 2014
Acquisition of Manchester laboratory
[1]Randox acquires a Manchester laboratory from Trimega Laboratories after Trimega enters administration.
- 1982
Randox is founded
[1]Peter FitzGerald establishes Randox in Crumlin, County Antrim, Northern Ireland.
Products and positioning
A vertically integrated, science-led diagnostics company combining laboratory products, specialist testing services and personalised-health offerings. Randox emphasizes breadth across clinical, molecular, forensic, veterinary and food-testing applications, supported by proprietary technology, manufacturing capacity and international distribution.
In vitro diagnostics
Clinical chemistry diagnostics
Randox supplies reagents, calibrators, controls and related laboratory products used in clinical chemistry workflows. These products support the measurement of biochemical markers in hospital, clinical and research laboratories and are designed to operate within professional laboratory systems.
In vitro diagnostics
Immunoassay diagnostics
The company’s immunoassay portfolio addresses laboratory testing that uses antigen-antibody reactions to detect or quantify analytes. It forms part of Randox’s broader supply of reagents and equipment for routine and specialist laboratory medicine.
Molecular diagnostics
Randox Molecular
Randox develops molecular and polymerase chain reaction testing solutions for clinical, research and public-health laboratories. The business became especially visible during the COVID-19 response, when it supplied large volumes of PCR-related testing to the United Kingdom.
Health testing services
Randox Health
Randox Health is the company’s public-facing health-testing operation. It provides consumer and clinical testing services connected with preventive health, diagnostic assessment and personalised-healthcare ambitions.
Forensic laboratory services
Forensic toxicology testing
Randox Testing Services has provided forensic toxicology analysis for criminal-justice and law-enforcement applications. This business became associated with a major data-integrity controversy that resulted in case reviews and a national retesting programme.
Laboratory supplies
Laboratory quality-control products
Randox produces quality-control materials and related products intended to help laboratories monitor analytical performance, validate processes and support reliable diagnostic results across multiple testing disciplines.
Controversies
2021
Employment and workplace disputes
Reported disputes included claims concerning weight discrimination, unfair dismissal, maternity pay and a workplace notice restricting languages other than English at the Donegal facility. The language notices were withdrawn after criticism.
2020
COVID-19 procurement and laboratory-operations scrutiny
Randox’s large non-competitive COVID-19 contracts and reported operational conditions attracted political, media and audit scrutiny. A television investigation raised allegations about processing, cross-contamination and worker safety, which Randox denied.
2019
Lobbying allegations involving Owen Paterson
Former cabinet minister and Conservative MP Owen Paterson, who worked as a Randox consultant, was reported to have contacted government bodies about issues related to testing contracts and policy. The contacts raised questions about parliamentary rules governing lobbying for paying clients.
2017
Randox Testing Services data-tampering controversy
Allegations of manipulated forensic toxicology data led to employee arrests, dropped prosecutions and reviews of thousands of criminal cases. Greater Manchester Police later said that up to 27,000 cases could potentially be affected.
Marketing campaigns
- 2024Type 1 diabetes genetic risk assessment advertising
United Kingdom
Randox promoted a genetic risk assessment assay for Type 1 diabetes. Critics raised concerns that the advertising relied on fear-based messaging to encourage testing.
Outcome. Randox removed the advertisements after concerns were reported.
- 2017Randox Health Grand National sponsorship
United Kingdom
Randox Health began sponsoring the Grand National at Aintree, giving the diagnostics brand prominent exposure through one of the United Kingdom’s best-known sporting events.
Outcome. The sponsorship continued to associate Randox Health with a major national sporting property.
Brand decisions
2022
Purchase and planned conversion of Boston HouseStrategyBackground
Randox sought a London base for education, research and personalised-healthcare activity.
Action taken
The company purchased Boston House in Fitzroy Square and planned to convert it into the Randox Institute.
Aftermath
The planned institute was positioned as an education centre focused on personalised healthcare.
Reported acquisition price and planned conversion spending. £29 million acquisition price; approximately £15 million further planned conversion spending (2022)
2020
Corporate restructuring through Randox (IOM) LtdStrategyBackground
The company reorganized its ownership structure during the period when it was expanding its operations and preparing for future ownership succession.
Action taken
Randox was restructured so that it was ultimately held by Randox (IOM) Ltd in the Isle of Man.
Aftermath
Randox said the structure would support a future transfer of ownership to later generations, while press reporting questioned its tax implications.
2020
Expansion into national COVID-19 testingProduct launchBackground
The UK government needed rapidly scalable laboratory capacity during the COVID-19 pandemic.
Action taken
Randox entered major government testing contracts and supplied PCR and related coronavirus tests.
Aftermath
The company supplied approximately 23 million tests and received reported government awards totaling about £777 million. The procurement and operational arrangements were later scrutinized by the National Audit Office and the media.
Reported UK government COVID-19 testing awards. Approximately £777 million in total reported awards (COVID-19 pandemic period through 2022 reporting)
2019
Move to Randox Science ParkStrategyBackground
Randox sought to consolidate and expand research and manufacturing capacity.
Action taken
The company moved into a 45-acre research and manufacturing complex at the former Massereene Barracks site.
Aftermath
The site became a central base for Randox’s research, engineering and production activities.
2014
Acquisition of Trimega laboratoryM&ABackground
Trimega Laboratories entered administration, creating an opportunity for Randox to acquire a Manchester laboratory and expand its laboratory-services presence.
Action taken
Randox acquired the laboratory and subsequently operated it as part of Randox Testing Services.
Aftermath
The operation later became central to the forensic toxicology data-integrity investigation.
Recent events
- 2024
Randox removes advertising for Type 1 diabetes genetic risk test[1]
Campaign · Regulation
Randox removed advertisements for a Type 1 diabetes genetic risk assessment assay after concerns that the campaign used fear to promote testing.
- 2021
Randox signs COVID-19 testing agreement with British Olympic Association[1]
Other
Randox entered a two-year agreement to provide COVID-19 testing for the British Olympic team.
- 2020
UK government awards Randox a major COVID-19 testing contract[1]
Other
The Department of Health and Social Care awarded Randox a reported £133 million coronavirus-testing contract without a competitive tender.
- 2020
MHRA requests precautionary recall of Randox COVID-19 home testing kit[1]
Recall · Regulation
The UK Medicines and Healthcare products Regulatory Agency requested a recall of the Randox COVID-19 Home Testing Kit because of safety concerns.
- 2020
Randox receives extension to UK COVID-19 testing contract[1]
Other
The United Kingdom awarded Randox a reported six-month, £347 million extension for COVID-19 testing without a public tender.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/randox · Editorial policy · How profiles are compiled